期刊
SCIENCE
卷 369, 期 6504, 页码 643-+出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abc5902
关键词
-
资金
- Netherlands Organization for Scientific Research (NWO) Vici grant
- Bill & Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (CAVD) [OPP1111923, OPP1132237, INV-002022, OPP1170236]
- Fondation Dormeur, Vaduz
- Health Holland PPS-allowance [LSHM20040]
- Netherlands Organisation for Health Research and Development (ZONMW)
- AMC Fellowship from Amsterdam UMC
- Amsterdam Institute for Infection and Immunity
- University of Amsterdam Proof of Concept fund [200421]
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as (tow micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据